TLR2 and Peritoneal Fibrosis: The therapeutic potential of inhibiting infection- or PDS-induced TLR activation to prevent peritoneal fibrosis development was evaluated by testing the ability of soluble Toll-like receptor 2 (sTLR2), a TLR inhibitor, to regulate peritoneal inflammation.